Literature DB >> 29075074

Percentage of Memory B Lymphocytes and Regulatory T Lymphocytes in Peripheral Blood are Low but Not Predictive of Therapy outcomes in Newly Diagnosed Adult Patients with Primary Immune Thrombocytopenia.

Mustafa Yilmaz1, Semiha Ayhan2.   

Abstract

Although changes in the number and function of regulatory T lymphocytes have been reported in primary immune thrombocytopenia (ITP), no study has investigated whether quantification of these cell types in peripheral blood could be used as early predictive marker of treatment outcome. And, it is not clear whether any change occurs in peripheral blood memory B lymphocyte levels in ITP. Hence, the aim of this study was to investigate the percentage of regulatory T lymphocytes and memory B lymphocytes in peripheral blood of ITP patients compared to controls, and also examine whether these levels have any significant predictive value for therapy outcome. A total of 20 newly diagnosed, untreated patients with ITP and 20 healthy controls were included. Flow cytometric analyses of lymphocyte subtypes in the peripheral blood were performed in specimens obtained from patients at the time of diagnosis and one month after the therapy initiation. First line corticosteroid (1 mg/kg/day methylprednisolone) therapy or splenectomy as second line treatment was performed, and patients were followed up for 3 years. Percentage of regulatory T lymphocytes (0.25 ± 0.17% vs. 1.14 ± 0.77%, P < 0.0001, n = 20) and percentage of memory B lymphocytes (1.57 ± 1.24% vs. 4.38 ± 2.41%, P < 0.001, n = 20) was significantly lower in ITP patients than healthy controls, at baseline. After one month therapy, the percentage of memory B lymphocytes of ITP patients significantly increased (from 1.66 ± 1.31% to 3.0 ± 1.7%, P < 0.009, n = 17). The initial value of regulatory T (0.33 ± 0.30%, n = 10 vs. 0.16 ± 0.05%, n = 7, P > 0.05) and memory B lymphocytes percentages (2.1 ± 1.8%, n = 10 vs. 1.1 ± 0.75%, n = 7, P > 0.05) were not significantly different for those who had complete response to first line therapy than those required splenectomy. These results indicate that regulatory T lymphocytes and memory B lymphocytes percentages are not useful for predicting treatment outcome in patients with newly diagnosed adult patients with ITP.

Entities:  

Keywords:  Memory B lymphocytes; Peripheral blood; Primary immune thrombocytopenia; Regulatory T lymphocytes; Therapy outcome prediction

Year:  2017        PMID: 29075074      PMCID: PMC5640538          DOI: 10.1007/s12288-017-0785-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  17 in total

1.  Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura.

Authors:  Bin Liu; Hui Zhao; Man-Chiu Poon; Zhibo Han; Dongsheng Gu; Maoqiang Xu; Hairong Jia; Renchi Yang; Zhong Chao Han
Journal:  Eur J Haematol       Date:  2007-02       Impact factor: 2.997

2.  [Alterations of CD4+ CD25+ regulatory T cells in patients with idiopathic thrombocytopenic purpura].

Authors:  Yun Ling; Xiang-Shan Cao; Zi-Qiang Yu; Guang-Hua Luo; Xia Bai; Jian Su; Lan Dai; Chang-Geng Ruan
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2007-03

3.  [Role of CD4(+) CD25(high) T cells in the pathogenesis of idiopathic thrombocytopenic purpura].

Authors:  Mi-Mi Shu; Xing-Mei Cao; Wang-Gang Zhang
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2008-08

4.  Abnormality of regulatory T-cells in remission and non-remission idiopathic thrombocytopaenic purpura patients.

Authors:  Hava Üsküdar Teke; Eren Gündüz; Olga Meltem Akay; Zafer Gülbas
Journal:  Platelets       Date:  2012-12-07       Impact factor: 3.862

5.  Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome.

Authors:  Arne Hansen; Marcus Odendahl; Karin Reiter; Annett M Jacobi; Eugen Feist; Jürgen Scholze; Gerd R Burmester; Peter E Lipsky; Thomas Dörner
Journal:  Arthritis Rheum       Date:  2002-08

Review 6.  B cells in autoimmunity.

Authors:  Thomas Dörner; Annett M Jacobi; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

7.  Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group.

Authors:  Kana Sakamoto; Hideki Nakasone; Shigeharu Tsurumi; Ko Sasaki; Kinuko Mitani; Michiko Kida; Akira Hangaishi; Kensuke Usuki; Ayako Kobayashi; Ken Sato; Mariko Karasawa-Yamaguchi; Koji Izutsu; Yasushi Okoshi; Shigeru Chiba; Yoshinobu Kanda
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

8.  Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95.

Authors:  Annett M Jacobi; Karin Reiter; Meggan Mackay; Cynthia Aranow; Falk Hiepe; Andreas Radbruch; Arne Hansen; Gerd-R Burmester; Betty Diamond; Peter E Lipsky; Thomas Dörner
Journal:  Arthritis Rheum       Date:  2008-06

9.  Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity.

Authors:  J W Semple; Y Milev; D Cosgrave; M Mody; A Hornstein; V Blanchette; J Freedman
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

Review 10.  Human regulatory T cells and autoimmunity.

Authors:  Cristina M Costantino; Clare M Baecher-Allan; David A Hafler
Journal:  Eur J Immunol       Date:  2008-04       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.